Molina Healthcare at UBS Global Healthcare Conference - MOLINA HEALTHCARE INC

Explicit Guidance:

• Earnings Build (Non-Guidance): FY2027 earnings per share (EPS) "building blocks" start at a base of $5.25 (FY2026 guidance) plus $4.00 of incremental "embedded earnings," resulting in a minimum target of $9.50 EPS. This excludes potential upside from Medical Loss Ratio (MLR) improvements in legacy Medicaid and assumes a 2026 MLR baseline of 92.6%.
• G&A Efficiency: FY2027 premium revenue expected to grow from $42 billion to $45 billion, driving $1.50 of per-share G&A efficiency gains.
• Revenue Growth: 2027 premium revenue forecast at $45 billion (up from $42 billion in 2026), fully accounting for a 6% membership headwind from new eligibility requirements (OB3).
• MLR Trend: 2026 MLR guidance is 92.6%; 2027 outlook assumes no change in the base case, with upside only if rates exceed trend.
• Rate & Trend Assumptions: FY2027 Medicaid rate growth projected at ~6% against a medical cost trend of 5.5–6.0%. Core trend stabilized at 4.5%, with additional 1.0–1.5% acuity shift pressure anticipated.

Business-Segment Outlook:

• Medicaid:
  • Membership: 6% membership decline expected for 2027 due to Obamacare Act (OB3) work requirements and biannual redeterminations; potential follow-on impact in 2028.
  • California: Federal regulation change expected in 2027 to revert undocumented immigration status members to fee-for-service, creating a $0.20–$0.25 per-share headwind.
  • Marginal Improvement: Expectation to recapture margin pressure if rate growth (6%) exceeds trend (5.5%), with states increasingly underfunding markets by ~300 bps necessitating rate catch-ups.
• Medicare:
  • Strategic Pivot: FY2027 marks the full transition to a dual-eligible (duals) focus only; exiting the general issue MAPD business (currently losing ~$1.00/share).
  • Profitability Harvest: Exiting the general issue business expected to add $1.00 to per-share earnings.
  • Growth Driver: Anticipated shift toward "Strong Form" Early Alignment Enrollment (EAE) in states, which favors integrated MCOs with strong Medicaid footprints.
• Florida Kids:
  • Path to Break-Even: Projected to move from a 5% pre-tax loss (Q4) to break-even in FY2027.
  • Drivers: Requires a 300 basis point improvement from Q4 levels (99% MLR with one-time reserves to ~97% core MLR), driven primarily by medical cost management.
• Marketplace:
  • Footprint Reduction: Exiting seven states, retaining a footprint of ~5 markets with meaningful local scale for 2027.
  • Strategy: Low exposure maintained until risk pool stability improves; current losses of $0.75/share expected to reach break-even in FY2027.

Market and Competitive Outlook:

• Competitive Advantage: Strong positioning in duals markets due to EAE requirements; ability to retain 90% of re-procurements and win 80% of new procurements.
• State Procurement Trends: Increased "referenceability" in RFPs, with states verifying historical performance in other jurisdictions; Molina's track record bodes well.
• Pricing Environment: States increasingly adjusting rates prospectively for acuity shifts; 80% of January 1 rate decisions known in draft or final form for FY2027.
• Market Volatility: Continued instability in the ACA Marketplace (rule changes, subsidy fluctuations) remains a primary constraint on re-investment; "stable risk pool" is a prerequisite for entry.

Macro / Industry Outlook:

• Political Climate: "Blue wave" in elections expected to facilitate state-level relaxation of work requirements and increase flexibility on frailty definitions, potentially softening the impact of disenrollment.
• Federal Gridlock: Congressional division (Democratic Senate/House but <60 seats) likely to cause legislative gridlock on major initiatives like OB3 subsidies or enhanced IRA changes.
• State Expansion: 10 non-expansion states may reconsider expansion, though funding constraints post-OB3 remain a hurdle.
• Regulatory Shifts: Potential bipartisan support for pharmacy transparency and No Surprises Act reforms (IDR).
• Economic Trends: Medicaid core trend stabilizing at 4.5% despite being higher than historical averages; LTSS, behavioral health, and high-cost drugs are primary trend drivers.

Strategic Initiatives:

• Embedded Earnings Harvesting: Targeting $4.00 of embedded earnings in FY2027:
  • $1.50 from Florida Kids contract normalization.
  • $1.00 from exiting MAPD general issue business.
  • $1.50 from G&A leverage on $3 billion revenue growth.
• M&A Appetite: Pipeline remains active, focusing on distressed non-profit plans and turnaround situations. Aiming to close transactions "soon" to capitalize on industry trough conditions.
• Capital Allocation: Priorities remain: 1) Organic growth, 2) M&A, 3) Share repurchases. Capital allocation strategy unchanged despite earnings recovery mode.
• Readiness: Georgia and Texas contract launches delayed from FY2027 to FY2028; costs and capital commitments already budgeted within FY2028 numbers.

Risks and Headwinds to Outlook:

• Membership Volatility: 6% membership decline in 2027 due to OB3 work rules, potentially with follow-on effects in 2028.
• Regulatory Headwinds: California fee-for-service reversion for undocumented members ($0.20–$0.25/share impact); potential delays or stricter enforcement of work requirements.
• Rate/Trend Imbalance: Risk that medical cost trend exceeds the projected 6% rate growth, compressing MLR margins.
• ACA Instability: Continued rule changes and subsidy uncertainty in the Marketplace could prevent the segment from achieving profitability or scale.
• Acquisition Execution: Delays in state contract certifications (e.g., Georgia, Texas) impacting timing of revenue recognition.

Management Tone on the Future:

• Confidence Level: "Cautious optimism"; management views 2026 as a trough with improvement anticipated in 2027.
• Forward-Looking Statements: Explicitly states that the "building blocks" to $9.50 are not formal guidance but a framework for investors to model.
• Earnings Seasonality: Typically 55–70% front-end loaded; 2027 earnings expected to follow this pattern, though specific seasonal breakdown not yet provided.
• Capital Position: Strong balance sheet ($600M cash at parent, debt-to-cap <45%) viewed as unconstrained; management confident in achieving 2.5% target margins in the strategic planning period.

Miscellaneous:

• G&A Management: Discipline on fixed vs. variable costs maintained even as revenue grows; 2027 expects $3B revenue growth to drive $1.50 per share G&A savings.
• Performance Benchmark: Historical outperformance of ~300 basis points over market competitors cited as a consistent differentiator.
• Florida Launch Timing: Florida CMS Kids implementation began October 1; Q4 expected to incur a 5% pre-tax loss, with break-even targeted for the full FY2027 cycle.